Y-mAbs Therapeutics reports Q2 EPS (21c), consensus (13c)

Reports Q2 revenue $22.8M, consensus $23.02M. “We demonstrated commercial progress with DANYELZA in the second quarter of this year while continuing to advance our development pipeline,” said Mike Rossi, President and CEO. “Our dedicated U.S. sales team with deep neuroblastoma expertise continues to penetrate new centers with DANYELZA, a leading anti-GD2 therapy, added to two more hospital formularies in the second quarter of 2024, while our ex-U.S. distribution partners have gained traction in our Eastern Asia and Latin America markets. Additionally, we remain focused on advancing our novel Self-Assembly DisAssembly Pretargeted Radioimmunotherapy technology platform and continue to evaluate potential expansion of indications for naxitamab in our mission of delivering better and safer therapies to patients. Looking ahead, we are on track to complete Part A of our GD2-SADA Phase 1 clinical trial in the fourth quarter of this year with a data readout to follow and are on track to dose the first patient in our CD38-SADA Phase 1 in Non-Hodgkin’s Lymphoma trial in the second half of this year.”